Document is current

Article History

Received: 10 July 2021

Revised: 23 November 2021

Accepted: 23 December 2021

First Online: 22 February 2022

Ethics approval and consent to participate

: All participating patients provided written informed consent. Both trials were approved by the German ethics boards and conducted in accordance with the Declaration of Helsinki.

: Not applicable.

: AdG reports honoraria and/or travel costs from AstraZeneca, MSD, Roche, Tesaro, Novartis, Pfizer, Eisai and DaichiiSankyo. WJ reports grants and personal fees from Sanofi-Aventis, grants and personal fees from Novartis, grants and personal fees from Lilly, grants and personal fees from Pfizer, grants and personal fees from Roche, grants and personal fees from Chugai, grants and personal fees from AstraZeneca, grants and personal fees from MSD, grants and personal fees from Daiichi-Sankyo, from null, during the conduct of the study. TWPF reports honoraria from Novartis. UN reports grants from Amgen, Celgene, Genomic Health, and Hoffmann La Roche, nonfinancial support from Allgemeine Ortskrankenkasse (public medical insurance scheme); personal fees from Agendia, Amgen, AstraZeneca, Celgene, Genomic Health, Pfizer, ands Roche as well as accommodation expenses from Roche, Pfizer, and Celgene; and is a shareholder of WSG GmbH (Study Group). BR reports institutional funding from Sanofi-Aventis, Chugai, Pfizer, GlaxoSmithKline und Janssen Diagnostics. AS reports grants from Celgene, grants from Roche, grants from AbbVie, personal fees from Roche, personal fees from AstraZeneca, personal fees from Celgene, personal fees from Roche, personal fees from Roche, personal fees from Celgene, personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Novartis, personal fees from MSD, personal fees from Tesaro, personal fees from Lilly, personal fees from Pfizer, other from Roche, outside the submitted work. TF reports Honoraria for lectures and/or consulting from AstraZeneca, Daiichi-Sankyo, MSD, Novartis, Pfizer, Roche, TEVA, Onkowissen, HK reports honoraria from Roche Pharma, Astra Zenca, Exact Science, Pfizer, Lilly, Novartis. SK reports personal fees and/or travel expenses from Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, F. Hoffmann‐La Roche Ltd, Genentech, Genomic Health, Lilly, MSD Oncology, Novartis, Pfizer, PFM Medical, Somatex and Sonoscope. ET reports travel expenses by Sandoz. RW reports honoraria as advisor, consultant and/or speaker as well as travel grants from Agendia, Amgen, Aristo, AstraZeneca, Boeringer Ingelheim, Carl Zeiss, Celgene, Clinsol, Daiichi-Sankyo, Eisai, ExactSciences, Genomic Health, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PumaBiotechnolgogy, Riemser, Roche, Sandoz/Hexal, Seattle Genetics, Tesaro Bio, Teva, Veracyte, Viatris. AH reports honoraria for lectures and/or consulting from Agendia, AstraZeneca, Daiichi-Sankyo, ExactSciences, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seattle Genetic, Teva. TR reports honoraria for lectures and/or advisory boards from AstraZeneca, Lilly, Novartis, Pfizer and Roche. PAF reports personal fees from Novartis, grants from Biontech, personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from AstraZeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from Seattle Genetics, personal fees from Roche, personal fees from Hexal, during the conduct of the study. OG reports honoraria for lectures and/or consulting from Roche, Novartis, Pfizer, Lilly, MSD, Amgen, Celgene/BMS, Exact Science, AstraZeneca, Pierre Fabre and travel expenses from Roche, Daiichi-Sankyo, Celgene. NH reports honoraria for lectures and/or consulting from AstraZeneca, Daiichi-Sankyo, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics. The remaining authors declare no competing interests.